Berahim

History

2023: Promomed buys controlling stake in Berahim

In early January 2023, it became known that the Promomed group of companies entered into an agreement to acquire 51% of shares in the chemical-pharmaceutical company Berakhim.

Since 2005, Berakhim has been developing and producing intermediates and active pharmaceutical substances (APIs). The priority area is the creation of peptide APIs. The company produces substances for angio- and hepatoprotectants, antidepressants, immunostimulants, as well as antiviral, antiparkinsonic and antitumor agents. The production site is located in Obninsk in the Kaluga region.

Promomed bought a controlling stake in Berakhim

The company successfully develops, cooperating with leading domestic and foreign manufacturers. The production and quality control of medicines are carried out in accordance with the requirements of GOST R 52249-2009 (GMP), the Berahim website says.

According to the Vedomosti newspaper, the deal to transfer 51% of Berahim's shares was closed on January 11, 2023. The seller was Natalya Belaya - the wife of Pyotr Beliy, the founder of the Promomed Group of Companies. At the same time, the other two co-owners of Berakhim - the founder of the company Yevgeny Chertorizhsky and the general director Irina Aksenova - retained their shares, amounting to 40% and 9%, respectively.

It is noted that the consolidation of Berahim's assets will allow Promomed to expand its opportunities to bring innovative products to the market. The range of the group includes more than 250 drugs, 80% of which are included in the list of vital and essential products. Over 100 new products are at different stages of development and registration. Promomed is one of the Russian leaders in the production of drugs for the treatment of COVID-19. In addition, the company is actively developing the direction of funds for weight regulation.^[1]

Notes